Klinische studies radiotherapie-oncologie

Overzicht van lopende klinische studies op onze dienst

Borsttumoren

  • NEO-CHECKRAY: Neo-adjuvant chemotherapy combined with stereotactic body radiotherapy to the primary tumour +/- durvalumab, +/- oleclumab in luminal B breast cancer: a phase ll randomised trial.
    Contact: Dr. Baten

Gastro-intestinale tumoren

  • EUS-guided fiducial marker placement in patients with esophageal cancer.
    Contact: Prof.dr. K. Haustermans
  • Novel strategies for organ-sparing in rectal cancer patients with complete response to radiochemotherapy.
    Contact: Prof.dr. K. Haustermans

Hersentumoren

  • Neurocognitive functioning in adult glioma patients.
    Contact: Prof.dr. M. Lambrecht

Hoofd- en halstumoren

  • SEMIRAHN: A prospective randomized phase 2 study of dose and volume de-escalation in prophylactic nodal irradiation of contralateral neck by sentinel lymph nodes mapping in unilaterally node positive head and neck squamous cell carcinomas.
    Contact: Prof.dr.J.-F. Daisne
    EORTC-1420-HNCG-ROG: Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma.
  • Contact: Prof.dr.S. Nuyts
    EORTC 1740-HNCG: Randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk HPV-positive locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC).
  • Contact: Prof.dr.S. Nuyts
    Debiopharm 1143-SCCHN-301: A randomized, double-blind placebo-controlled, phase III study of Debio 1143 in combination with platinum-based concomitant standard fractionation IMRT chemoradiotherapy (CRT) in high-risk patient with unresectable, locally advanced squamous cell carcinoma of the head and neck.
  • Contact: Prof.dr.S. Nuyts
    CSEP: Improving health-related quality of life of head and neck cancer patients via a dedicated comprehensive supervised exercise program.
  • Contact: Prof.dr.S. Nuyts
    EffEx-HN: Effect of Exercise in Head and Neck Cancer Patients.
  • Contact: Prof.dr.S. Nuyts

Longtumoren

  • LAT-FLOSI: Local ablative therapy for oligoprogressive non-small-cell lung cancer treated with first-line osimertinib.
    Contact: Dr. P. Berkovic
  • Cross-sectional study investigating fatigue, psychological stress and neurocognitive functioning after immunotherapy in non-small cell lung cancer patients.
    Contact: Prof.dr. M. Lambrecht

Niet-ziekte specifieke studies

  • LAT-MUM: Local ablative therapy for patients with multiple (4-10) brain metastases.
    Contact: Dr. P. Berkovic
  • E²-RADIATE - OligoCare: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients.
    Contact: Prof.dr.J.-F. Daisne

Prostaattumoren

  • PART: Elective para-aortic radiotherapy (PART) for pN1 prostate cancer: a phase 2 trial using Arc therapy (IMAT / VMAT).
    Contact: Prof.dr. G. De Meerleer
  • LOBSTER: A multicentre, randomized, prospective phase II study to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in patients with biochemical relapse after radical prostatectomy.
    Contact: Prof.dr. G. De Meerleer
  • OBELIX: Observational study on extreme hypofractionation for localized prostate cancer.
    Contact: Prof.dr. G. De Meerleer
  • SPARKLE: Metastasis-directed therapy for oligocurrent prostate cancer: a randomized phase III trial.
    Contact: Prof.dr. G. De Meerleer
  • Salie studie: Evaluation of the efficacy and safety of tegaranavir in controlling hot flashes in prostate cancer patients treated with androgen deprivation therapy.
    Contact: Prof.dr. G. De Meerleer
Laatste aanpassing: 29 april 2022